Media Doctor Canada
Follow us on Twitter








"Regulating blood sugar with one shot a week"

Globe and Mail

Source: Globe and Mail

Published: 09 Sep 2022

Category: Pharmaceutical

Rating: (5 stars)

what they said (Hover the mouse cursor over underlined words for more info)

A once-a-week injectable diabetes drug appears to lower blood sugar somewhat better than the same drug injected twice daily, creating promise that the new formulation may be a more useful part of a Type 2 diabetes control regime, a new study suggests.

The drug, exenatide, also has the advantage of triggering modest weight loss - an average of just over 3.5 kilograms - in people taking it, making it the only available diabetes drug to do so. While some diabetes drugs are "weight neutral," most cause weight gain, which can complicate diabetes control and undermine a person's willingness to take the medication...

The original article can be found at:

how did it rate? (more information)

Criteria Rating
Total Score 9 of 9
Availability of Treatment Satisfactory (?)
Novelty of Treatment Satisfactory (?)
Disease Mongering Satisfactory (?)
Treatment Options Satisfactory (?)
Costs of Treatment Not Applicable
Evidence Satisfactory (?)
Quantification of Benefits of Treatment Satisfactory (?)
Harms of Treatment Satisfactory (?)
Sources of Information Satisfactory (?)
Relies on Press Release Not Applicable
Quantification of Harms of Treatment Satisfactory (?)

what we said (Hover the mouse cursor over underlined words for more info)

This story included some really good elements and serves as a good example for health-related journalism. Not only did it include a good description of the evidence, but it also appropriately described both the benefits (in absolute and relative terms) and the risks associated with the new drug exenatide. The article successfully outlined the sources of information and was clear in stating that this new product was not yet on the Canadian market. While some might argue that the overall treatment of diabetes in mass media does border on disease mongering, the article did not show any obvious elements of this criterion.

Although exenatide is not yet available in Canada, the comprehensiveness nature of this report provides readers with information necessary to making an informed decision about this treatment option.

public forum

There are currently no comments on this article.

voice your opinion in the forum

  • All comments and feedback submitted to Media Doctor are subject to editorial approval before being made viewable by the public. It may take up to a week for your comments to be approved. Additionally, no response will be given to questions posed in public comments. Media Doctor does not provide medical advice, or answers to medical questions posed by the public.
  • If you provide your email address it will not be displayed to the general public.
  • Comments may be edited by Media Doctor to remove defamatory or sensitive statements, and brand names.
  • Required fields are marked with an asterisk (*).
Name: *
Comments: *
Copyright © Media Doctor Canada